Healthcare
Live Price
Offline$14.62
+0.00% today
1Y Change
-9.75%
Window
Jun 20, 2025 → Jun 12, 2026
Coverage: 246 bars · Jun 20, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Terumo Corporation (TRUMF) is a Healthcare stock with a market cap of $2.93T and listed on OTC. The stock last traded around $14.62 and down 9.8% across the available one-year price window (Jun 20, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +12.4%, EPS growth of +10.5%, a dividend yield of 1.5%. What stands out right now is revenue +12.4%, EPS +10.5%, free cash flow +90.1% with operating margin 17.2% and ROIC 7.1%. The dividend is present but secondary, with a yield around 1.5%. Valuation is more restrained than many high-expectation growth names at P/E 22.9 and price/sales 2.7. Stock Foundry combines TRUMF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TRUMF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TRUMF Max Drawdown
-43.09%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TRUMF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$613.8B
-12.7% YoY
FY Net Income
$77.3B
-13.0% YoY
Free Cash Flow
$38.4B
-43.1% YoY
Revenue Growth
+12.4%
EPS Growth
+10.5%
Gross Margin
53.3%
Net Margin
11.7%
Income statement
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1036.2B | 921.9B | 820.2B | 703.3B | 613.8B |
| Gross Profit | 560.7B | 479.2B | 417.4B | 369.3B | 326.6B |
| Operating Income | 157.7B | 140.1B | 117.3B | 116.0B | 98.4B |
| EBITDA | 246.3B | 220.3B | 190.4B | 175.5B | 153.3B |
| Net Income | 117.0B | 106.4B | 89.3B | 88.8B | 77.3B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 221.9B | 204.9B | 187.3B | 205.3B | 200.8B |
| Total Assets | 1828.4B | 1831.4B | 1602.2B | 1473.7B | 1351.2B |
| Total Liabilities | 459.9B | 504.3B | 491.2B | 461.4B | 494.5B |
| Shareholder Equity | 1368.5B | 1327.1B | 1111.1B | 1012.3B | 856.7B |
| Total Debt | 174.8B | 268.5B | 266.7B | 259.0B | 293.1B |
| Net Debt | -47.0B | 63.7B | 79.3B | 53.8B | 92.3B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
121.5B
-14.1% YoY
Capital Expenditures
83.1B
-12.2% YoY
Free Cash Flow
38.4B
-43.1% YoY
Key ratios
Gross Margin
53.3%
Operating Margin
17.2%
Net Margin
11.7%
ROE
9.0%
Debt / Equity
0.26x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.